FDA Takes Aim at Delaying Tactics for Shared REMS

Generic Line
A A
The FDA is working to prevent manufacturers of branded high-risk drugs from stalling an application for approval of a generic competitor via manipulation of a requirement to share safety programs, Commissioner Scott Gottlieb said.

To View This Article:

Login

Subscribe To Generic Line